(Q35989381)

11 August 2017

1 reference

title

Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus (English)

1 reference

11 August 2017

0 references

0 references

Helmut Walter

1

1 reference

PubMed ID

15610048

11 August 2017

Georg Lübben

series ordinal

2

1 reference

11 August 2017

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

65

1 reference

11 August 2017

1

1 reference

11 August 2017

1-13

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565010-00001

11 August 2017

0 references

cites work

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

12 December 2020

The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Study.

1 reference

12 December 2020

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

12 December 2020

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation

1 reference

12 December 2020

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

12 December 2020

Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans

1 reference

12 December 2020

Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle

1 reference

12 December 2020

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

beta-cell turnover: its assessment and implications

1 reference

12 December 2020

Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project

1 reference

12 December 2020

Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM.

1 reference

12 December 2020

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

12 December 2020

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

1 reference

12 December 2020

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress

1 reference

12 December 2020

Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

12 December 2020

PPARgamma, the ultimate thrifty gene

1 reference

12 December 2020

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

1 reference

12 December 2020

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release

1 reference

12 December 2020

Troglitazone stimulates pancreatic growth in normal rats

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

1 reference

12 December 2020

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

1 reference

12 December 2020

Unraveling the mechanism of action of thiazolidinediones

1 reference

12 December 2020

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

1 reference

12 December 2020

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells

1 reference

12 December 2020

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

12 December 2020

Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma

1 reference

12 December 2020

Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

1 reference

12 December 2020

Beta-cell deterioration--prospects for reversal or prevention

1 reference

12 December 2020

Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus.

1 reference

12 December 2020

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

1 reference

12 December 2020

Direct antidiabetic effect of leptin through triglyceride depletion of tissues.

1 reference

12 December 2020

The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation

1 reference

12 December 2020

Pancreatic beta-cell loss and preservation in type 2 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells

1 reference

12 December 2020

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

12 December 2020

Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

1 reference

12 December 2020

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

12 December 2020

Tumor necrosis factor alpha inhibits signaling from the insulin receptor

1 reference

12 December 2020

TNF-alpha and insulin resistance: summary and future prospects

1 reference

12 December 2020

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.

1 reference

12 December 2020

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

1 reference

12 December 2020

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

12 December 2020

Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene

1 reference

12 December 2020

Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships

1 reference

12 December 2020

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

1 reference

12 December 2020

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

1 reference

12 December 2020

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

1 reference

12 December 2020

Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes

1 reference

12 December 2020

Beta-cell mass plasticity in type 2 diabetes.

1 reference

12 December 2020

Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

1 reference

12 December 2020

Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility

1 reference

12 December 2020

Lipotoxicity in human pancreatic islets and the protective effect of metformin

1 reference

12 December 2020

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

1 reference

12 December 2020

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

12 December 2020

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

1 reference

12 December 2020

Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study

1 reference

12 December 2020

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

12 December 2020

Palmitate and myristate selectively mimic the effect of glucose in augmenting insulin release in the absence of extracellular Ca2+

1 reference

12 December 2020

Chronic effects of different fatty acids and leptin in INS-1 cells

1 reference

12 December 2020

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

12 December 2020

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

12 December 2020

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

12 December 2020

Fatty acids, lipotoxicity and insulin secretion

1 reference

12 December 2020

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

1 reference

12 December 2020

10.2165/00003495-200565010-00001

Identifiers

DOI

1 reference

PubMed ID

15610048

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15610048